Press Releases & News
Recent News:Allow us to wish you a fine new year and take this opportunity to advise you of significant developments at CVPath Institute. Beginning in December 2016, we will begin to offer micro-computerized tomography (CT) services in-house. We have acquired a state-of-the-art Nikon XTH 225 ST for high-speed computerized tomography and real-time X ray visualization. This service will be available to all clients for all tissues and we anticipate that it will lower our turnaround time for specimens undergoing CT as well as histological analysis. This will eliminate the need to send tissues away for CT analysis. Micro CT will also be offered as a stand-alone service. We have also acquired a state-of-the-art Zeiss 880 high resolution confocal microscope for cellular imaging. This is allowing us to understand in ways we never have before the function of regenerated endothelial layer that covers stents and to investigate other areas of cardiovascular biology pertinent to vascular disease and its treatment. Below we have provided an example where we have stained a rabbit iliac implanted with a drug-eluting stent with antibodies against the endothelial junctional protein VE-cadherin (shown in red) and the beta-catenin which stabilizes VE-cadherin p120 (shown in green). You can see that the two proteins co-localize at the borders of endothelial cells. A side branch is shown in the center of the picture. Of the many publications written by the CVPath team this past year we would like to point your attention to a review in Nature Reviews Cardiology Pathophysiology of native, vein graft, and in-stent atherosclerosis highlighting pathological differences in these three vascular disease entities. In addition, Drs. Finn and Virmani wrote 2 editorials in the Lancet this year on important clinical trials in the field of interventional cardiology. The first pertained to a meta-analysis of 6 clinical trials published in November comparing outcomes using the Abbott bioabsorable vascular scaffold (BVS, Absorb) versus the permanent polymer everolimus eluting stent. The editorial highlights concerns regarding increase rates of early stent thrombosis seen in patients receiving BVS but also the potential benefits of such a device. The second editorial pertains to a clinical trial comparing outcomes in bioabsorable polymer drug eluting stents versus permanent polymer drug-eluting stents. The editorial puts forth our opinion on the potential benefits of a bioabsorable polymer metallic stents and was published in October 2016.
November 21, 2016
Dear Colleagues, Friends and Sponsors,
We would like to take this opportunity to inform you of a new state-of-the-art non-destructive imaging capability that we have recently added to the Institute. Beginning December 2016, CVPath will offer micro-computerized tomography (CT) as a stand alone service in-house. We have acquired an advanced Nikon XTH 225 ST micro-CT for high-speed computerized tomography and real-time Xray visualization. This service will be available to all clients for all tissues in the anticipation of providing the best quality of imagery in the mCT arena in addition to improving the turnaround time for specimens undergoing mCT as well as histology evaluation.
For further information about capabilities and costs, please contact myself or Dr. Kolodgie (or simply email CT@cvpath.org).
We look forward to continuing to work with you and we greatly appreciate your support.
Aloke Finn, MD
Medical Director-CV Path Institute
19 Firstfield Road
Gaithersburg, MD 20878
Main: 301 208 3570
Direct: 301 208 2495
Fax: 301 208-3745